Interested in the Genedrive share price? Read this first!

The Genedrive share price has produced large returns for investors this year, but can the company continue to outperform?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Genedrive (LSE: GDR) share price has been on a rollercoaster ride this year. The stock was trading at around 9p a share in March but then leapt to more than 200p in early May. 

The excitement started to build around the company due to its existing technology, which could identify pathogens relatively quickly. This technology, investors speculated, could help revolutionise the testing process for Covid-19. The organisation believed it could cut delays processing lab samples.

Unfortunately, the company’s progress has been slower than many investors may have projected. The practicalities of getting accurate products to market have hampered the business.

Consequently, these delays hurt investor sentiment towards the Genedrive share price. The stock has fallen as a result, currently changing hands at just over 111p, down around 50% from that May high. 

Steady progress 

Despite the slow progress, Genedrive is pushing forward. Following the CE marking of the Genedrive 96 SARS-CoV-2 kit at the end of May, management has been working to gain approval from regulators around the world to sell the product in different markets.

In the United States, Emergency Use Authorisation (EUA) has been applied for and remains under consideration by the FDA. Meanwhile, the approval process in Africa and India is well underway. The South African Health Products Regulatory Authority also approved the product at the end of September. 

The firm has also signed an agreement with Beckman Coulter Life Sciences to combine the Genedrive 96 SARS Cov 2 testing kit with the Biomek i7 automated work station. 

And on top of all of the above, Genedrive is working on a new Point-of-Care (POC) system for Covid-19. This product could produce results in approximately 15 minutes. 

Unlike many other early-stage healthcare companies, the business already has revenue commitments. Its latest trading update noted the firm had £1m of purchase commitments for the Genedrive 96 SARS-CoV-2 kit. Unfortunately, the company also noted it needs regulatory approval before these orders can be filled. 

Genedrive share price investment potential 

Still, from an investment perspective, I think the Genedrive share price looks attractive. One of the most common reasons why early-stage healthcare companies fail is lack of funds. That’s not something investors here need to be worried about right now.

At the end of June, Genedrive had £8.2m of cash on the balance sheet. I think that could be enough to sustain the business for at least two years. The company should have reached the revenue stage by that point. From there on, the sky could be the limit for Genedrive. 

As such, while the Genedrive share price has fallen in recent months, I think the firm’s fundamentals look much stronger today than they were at the beginning of the year. If the company’s testing products are approved around the world, the revenue opportunity could be substantial.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Should I follow Warren Buffett and sell my favourite shares?

Billionaire US investor Warren Buffett has been selling tons of Apple shares and other stocks of businesses he thinks are…

Read more »

Investing Articles

As like-for-like sales continue to fall, is the B&M European Value Retail SA (LSE:BME) share price a bargain?

B&M European Value Retail is known for its low prices, but could growing like-for-like sales make the share price the…

Read more »